1.Medium- and long-term efficacy of percutaneous mechanical thrombectomy with stent implantation in patients with iliac vein stenosis and thrombosis.
Chunlun CHEN ; Chenyang QIU ; Lan SHEN ; Renda ZHU ; Huaji ZHOU ; Hongkun ZHANG
Journal of Zhejiang University. Medical sciences 2025;54(1):108-114
OBJECTIVES:
To investigate the medium- and long-term efficacy of percutaneous mechanical thrombectomy (PMT) combined with stent implantation for treatment of iliac vein stenosis with lower extremity deep venous thrombosis (LEDVT).
METHODS:
Clinical and follow-up data of 125 patients with iliac vein stenosis and LEDVT who underwent PMT and stent implantation at five hospitals in northern Zhejiang province from January 2017 to June 2021 were collected. The thrombus clearance rate, thrombus recurrence rate, patency rate of iliac vein stents and post-thrombotic syndrome (PTS) occurrence rate were documented, and safety indicators such as bleeding, death, pulmonary embolism, stent fracture and displacement were assessed.
RESULTS:
Among 125 patients, for clearance of limb thrombosis, there were 8 cases of grade I (6.4%), 10 cases of grade II (8.0%), and 107 cases of grade III (85.6%). Patients were followed up for a median period of 74 months. According to the Villalta score, the recurrence rates of limb thrombosis at 12, 24 and 36 months were 8.48%, 8.93% and 10.91%; the iliac vein patency rates were 91.52%, 91.07%, and 89.09%; and the incidences of PTS were 5.08%, 5.36% and 6.36%, respectively. There were no major adverse events such as death, massive pulmonary embolism or severe hepatic and renal insufficiency, and no readmission intervention events due to stent fracture or other incidence were found.
CONCLUSIONS
PMT combined with iliac vein stent implantation is effective for patients with iliac vein stenosis complicated by LEDVT with good medium- and long-term efficacy and safety, which is worthy of clinical application.
Humans
;
Stents
;
Iliac Vein/pathology*
;
Venous Thrombosis/surgery*
;
Thrombectomy/methods*
;
Female
;
Male
;
Middle Aged
;
Aged
;
Adult
;
Constriction, Pathologic/surgery*
;
Treatment Outcome
;
Follow-Up Studies
2.Celastrus orbiculatus Extract Inhibits Immune Inflammatory Thrombotic State of B-Lymphoma.
Miao ZHU ; Qing-Qing SHI ; Jun NI ; Wei WU ; Xing SUN ; Mei SUN ; Kai-Lin XU ; Yan-Qing LIU ; Jian GU ; Hao GU
Chinese journal of integrative medicine 2024;30(11):1018-1026
OBJECTIVE:
To investigate the inhibitory effect of Celastrus orbiculatus extracts (COE) on the proliferation of lymphoma cells and the immune regulation ability on inflammation and thrombophilia in vivo.
METHODS:
The 38B9 lymphoma cells were treated with COE (160 µ g/mL) and CTX (25 µ mol/L). The apoptosis rate and cell cycle of each group were detected by flow cytometry. The secretion of inflammatory factors, including interleukin (IL)-6, IL-10, and tumor necrosis factor α (TNF-α), in cell supernatant was detected by enzyme-linked immunosorbent assay (ELISA). In vivo, BALB/c mice were subcutaneously injected with 38B9 lymphoma cells to establish lymphoma model. COE (3 mg·kg-1·d-1) and CTX (40 mg·kg-1·d-1) were administered to the model mice, respectively. The expression of plasma inflammatory factors (IL-6, IL-10 and TNF-α) and thrombus indexes, including D-dimer (D-D), von Willebrand factor (vWF) and tissue factor (TF), were detected by ELISA before tumor bearing (1 d), after tumor formation (14 d) and after intervention (21 d). PicoGreen dsDNA was used to detect the level of serum neutrophil extracellular traps (NETs). Flow cytometry was used to detect the expression of platelet activation marker calcium-dependent lectin-like receptor 2 (CLEC-2). The tumor growth and survival of mice were recorded.
RESULTS:
The 38B9 lymphoma cells were apoptotic after the intervention of COE and CTX. The ratio of G2-M phase cells decreased in COE intervented cells compared with the control cells (P<0.05), and S phase cells decreased in CTX intervented cells (P<0.05). Also, the secretion level of IL-6 was significantly reduced after COE or CTX intervention (P<0.05), and IL-10 was significantly increased (P<0.05). Furthermore, the tumor mass was reduced, and the median survival time was longer in COE and CTX intervented tumor-bearing mice than in non-intervented mice. The significantly lower levels of TNF-α, IL-6, NETs, TF, DD and CLEC-2, as well as higher IL-10 were observed in COE and CTX treatment mice in comparision with the control mice (P<0.05).
CONCLUSION
COE has a mild and stable anti-tumor effect, which can reduce the secretion of inflammatory factors by lymphoma cells and regulate thrombophilic state caused by tumor inflammatory microenvironment.
Animals
;
Plant Extracts/pharmacology*
;
Mice, Inbred BALB C
;
Thrombosis/drug therapy*
;
Celastrus/chemistry*
;
Cell Line, Tumor
;
Lymphoma, B-Cell/pathology*
;
Apoptosis/drug effects*
;
Inflammation/pathology*
;
Cell Proliferation/drug effects*
;
Mice
;
Cell Cycle/drug effects*
;
Male
;
Cytokines/metabolism*
;
Inflammation Mediators/metabolism*
3.Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus.
Dong LAN ; Zhuo LIU ; Yu Xuan LI ; Guo Liang WANG ; Xiao Jun TIAN ; Lu Lin MA ; Shu Dong ZHANG ; Hong Xian ZHANG
Journal of Peking University(Health Sciences) 2023;55(5):825-832
OBJECTIVE:
To investigate and analyze the risk factors of massive hemorrhage in patients with renal cell carcinoma and venous tumor thrombus undergoing radical nephrectomy and removal of venous tumor thrombus.
METHODS:
From January 2014 to June 2020, 241 patients with renal cancer and tumor thrombus in a single center of urology at Peking University Third Hospital were retrospectively analyzed. All patients underwent radical nephrectomy and removal of venous tumor thrombus. The relevant preoperative indicators, intraoperative conditions, and postoperative data were statistically analyzed by using statistical software of SPSS 18.0. The main end point of the study was intraoperative bleeding volume greater than 2 000 mL. Logistic regression analysis was used to determine the relevant influencing factors. First, single factor Logistic regression was used for preliminary screening of influencing factors, and variables with single factor Logistic regression analysis P < 0.05 were included in multivariate Logistic regression. In all statistical analyses, P < 0.05 is considered statistically significant.
RESULTS:
Among the 241 patients included, there were 60 cases of massive hemorrhage, 48 males and 12 females, with a median age of 62 years. The number of non-massive hemorrhage was 181. There were 136 males and 45 females, with a median age of 59 years. Univariate analysis showed that the clinical symptoms (both systemic and local symptoms, OR 2.794, 95%CI 1.087-7.181, P=0.033), surgical approach (open surgery, OR 9.365, 95%CI 4.447-19.72, P < 0.001), Mayo grade (Mayo 3-4, OR 5.257, 95%CI 2.806-10.886, P < 0.001), American Society of Anesthesiologists (ASA) score (ASA level 3, OR 2.842, 95%CI 1.338-6.036, P=0.007), preoperative hemoglobin (OR 0.978, 95%CI 0.965-0.991, P=0.001), preoperative platelet count (OR 0.996, 95%CI 0.992-1.000, P=0.037), maximum tumor thrombus width (OR 1.061, 95%CI 1.033-1.091, P < 0.001), Complicated with bland thrombus (OR 4.493, 95%CI 2.264-8.915, P < 0.001), adrenalectomy (OR 3.101, 95%CI 1.614-5.958, P=0.001), segmental resection of the inferior vena cava (OR 2.857, 95%CI 1.395-5.852, P=0.004). There was a statistically significant difference in these aspects(P < 0.05). Multivariate Logistic regression analysis showed that there was a statistically significant difference in surgical approach (open surgery, OR 6.730, 95%CI 2.947-15.368;P < 0.001), Mayo grade (Mayo 3-4, OR 2.294, 95%CI 1.064-4.948, P=0.034), Complicated with bland thrombus (OR 3.236, 95%CI 1.492-7.020, P=0.003).
CONCLUSION
Combining the results of univariate and multivariate Logistic regression analysis, the surgical approach, Mayo grade, and tumor thrombus combined with conventional thrombus were associated risk factors for massive hemorrhage during surgery for renal cell carcinoma with tumor thrombus. Patients who undergo open surgery, high Mayo grade, and tumor thrombus combined with conventional thrombus are at a relatively higher risk of massive hemorrhage.
Male
;
Female
;
Humans
;
Middle Aged
;
Carcinoma, Renal Cell/pathology*
;
Retrospective Studies
;
Thrombosis/etiology*
;
Kidney Neoplasms/pathology*
;
Vena Cava, Inferior/surgery*
;
Nephrectomy/methods*
;
Thrombectomy/methods*
;
Risk Factors
;
Hemorrhage
4.SpyGlass in Diagnosis of Hepatocellular Carcinoma with Right Hepatic Duct Tumor Thrombus Hemorrhage: A Case Report.
Li-Hua GUO ; Min MIAO ; Guo-Liang YE
Chinese Medical Sciences Journal 2023;38(4):309-314
Hepatocelluar carcinoma presenting as a biliary duct tumor thrombus is a relatively rare entity, with poor prognosis. The primary clinical manifestation of this disease is obstructive jaundice, which can often be misdiagnosed. A 59-year-old female patient was admitted with sudden onset of abdominal pain. Laboratory tests suggested obstructive jaundice, and enhanced magnetic resonance imaging of the upper abdomen did not show obvious biliary dilatation. Endoscopic ultrasound and endoscopic retrograde cholangiopancreatography suggested an occupying lesion in the upper bile duct. SpyGlass and biopsy finally confirmed hepatocellular carcinoma with right hepatic duct tumor thrombus hemorrhage. The SpyGlass Direct Visualization System, as an advanced biliary cholangioscopy device, showed the advantages of single-person operation as well as easy access to and visualization of the lesion.
Female
;
Humans
;
Middle Aged
;
Carcinoma, Hepatocellular/diagnostic imaging*
;
Jaundice, Obstructive/etiology*
;
Liver Neoplasms/diagnostic imaging*
;
Hepatic Duct, Common/pathology*
;
Thrombosis/complications*
;
Hemorrhage/complications*
5.Efficacy evaluation of novel oral anticoagulants in patients with cirrhosis accompanied with portal vein thrombosis: a meta-analysis.
Xiao Tong XU ; Yu Wei LIU ; Jing Lan JIN
Chinese Journal of Hepatology 2023;31(6):614-620
Objective: To analyze the safety and efficacy of using novel oral anticoagulants (rivaroxaban and others) in patients with cirrhosis accompanied with portal vein thrombosis (PVT). Methods: Clinical research literature published from the establishment of the database to June 20, 2021, was retrieved from PubMed, Web of Science, CNKI, Wanfang, and Weipu databases by combining subject terms and free words. RevMan software was used for the random group meta-analysis model. Results: In terms of PVT recanalization, the novel oral anticoagulants (such as low molecular weight heparin and others) had a higher recanalization rate than traditional anticoagulants (OR = 13.75, 95%CI 3.58-52.9, P = 0.000 1). In terms of bleeding, the novel oral anticoagulants did not increase the risk of bleeding compared with traditional anticoagulants (OR = 2.42, 95%CI 0.62-9.41, P = 0.20). Conclusion: The novel oral anticoagulant drugs are superior to traditional anticoagulants in terms of the occurrence of PVT recanalization; however, there is no statistically significant difference in terms of the occurrence of bleeding between the two groups.
Humans
;
Portal Vein/pathology*
;
Treatment Outcome
;
Venous Thrombosis/complications*
;
Liver Cirrhosis/pathology*
;
Anticoagulants/therapeutic use*
;
Hemorrhage
6.The combination of EGCG with warfarin reduces deep vein thrombosis in rabbits through modulating HIF-1α and VEGF via the PI3K/AKT and ERK1/2 signaling pathways.
Yan LI ; Jing-Ping GE ; Ke MA ; Yuan-Yuan YIN ; Juan HE ; Jian-Ping GU
Chinese Journal of Natural Medicines (English Ed.) 2022;20(9):679-690
Deep venous thrombosis (DVT) poses a major challenge to public health worldwide. Endothelial cell injury evokes inflammatory and oxidative responses that contribute to thrombus formation. Tea polyphenol (TP) in the form of epigallocatechin-3-gallate (EGCG) has anti-inflammatory and oxidative effect that may ameliorate DVT. However, the precise mechanism remains incompletely understood. The current study was designed to investigate the anti-DVT mechanism of EGCG in combination with warfarin (an oral anticoagulant). Rabbits were randomly divided into five groups. A DVT model of rats was established through ligation of the inferior vena cava (IVC) and left common iliac vein, and the animals were orally administered with EGCG, warfarin, or vehicle for seven days. In vitro studies included pretreatment of human umbilical vein endothelial cells (HUVECs) with different concentrations of EGCG for 2 h before exposure to hydrogen peroxide. Thrombus weight and length were examined. Histopathological changes were observed by hematoxylin-eosin staining. Blood samples were collected for detecting coagulation function, including thrombin and prothrombin times, activated partial thromboplastin time, and fibrinogen levels. Protein expression in thrombosed IVCs and HUVECs was evaluated by Western blot, immunohistochemical analysis, and/or immunofluorescence staining. RT-qPCR was used to determine the levels of AGTR-1 and VEGF mRNA in IVCs and HUVECs. The viability of HUVECs was examined by CCK-8 assay. Flow cytometry was performed to detect cell apoptosis and ROS generation was assessed by 2',7'-dichlorofluorescein diacetate reagent. In vitro and invivo studies showed that EGCG combined with warfarin significantly reduced thrombus weight and length, and apoptosis in HUVECs. Our findings indicated that the combination of EGCG and warfarin protects HUVECs from oxidative stress and prevents apoptosis. However, HIF-1α silencing weakened these effects, which indicated that HIF-1α may participate in DVT. Furthermore, HIF-1α silencing significantly up-regulated cell apoptosis and ROS generation, and enhanced VEGF expression and the activation of the PI3K/AKT and ERK1/2 signaling pathways. In conclusion, our results indicate that EGCG combined with warfarin modifies HIF-1α and VEGF to prevent DVT in rabbits through anti-inflammation via the PI3K/AKT and ERK1/2 signaling pathways.
Animals
;
Anticoagulants/pharmacology*
;
Catechin/analogs & derivatives*
;
Eosine Yellowish-(YS)/pharmacology*
;
Fibrinogen/pharmacology*
;
Hematoxylin/pharmacology*
;
Human Umbilical Vein Endothelial Cells
;
Humans
;
Hydrogen Peroxide/pharmacology*
;
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism*
;
MAP Kinase Signaling System
;
Phosphatidylinositol 3-Kinases/metabolism*
;
Polyphenols/pharmacology*
;
Proto-Oncogene Proteins c-akt/metabolism*
;
RNA, Messenger
;
Rabbits
;
Rats
;
Reactive Oxygen Species/metabolism*
;
Signal Transduction
;
Sincalide/pharmacology*
;
Tea
;
Thrombin/pharmacology*
;
Vascular Endothelial Growth Factor A/metabolism*
;
Venous Thrombosis/pathology*
;
Warfarin/pharmacology*
7.The Role of Platelet Exosomes in Atherogenic Thrombosis --Review.
Dong-Lian TAO ; Shan DENG ; Yue HU ; Xiu-Quan WU ; Yi-Jian CHEN
Journal of Experimental Hematology 2022;30(3):975-978
Exosomes are subtypes of extracellur vesicles containing a variety of cell-specific proteins, lipids and nucleic acids released during cell activation or apoptosis, and play the role of intercellur communication mediators in different physiological and pathological processes. With the development of research in recent years, the role of platelet-derived exosomes in cardiovascular diseases has attracted extensive attention. This paper reviews the role of platelet-derived exosomes in atherosclerotic thrombosis and the potential role of platelet-derived exosomes as biomarkers for the diagnosis and treatment of atherosclerotic thrombotic disease and the problems to be solved.
Apoptosis
;
Atherosclerosis/pathology*
;
Blood Platelets/pathology*
;
Exosomes/pathology*
;
Humans
;
Thrombosis
8.Coagulation Disorders in Bullous Pemphigoid and Its Mechanism.
Acta Academiae Medicinae Sinicae 2019;41(5):685-689
Bullous pemphigoid(BP)is an autoimmune blister disease caused by antibodies to the basement membrane zone.It usually exhibits tense bullae in skin and mucous membrane.BP patients can suffer from thrombosis due to hypercoagulation and/or hemorrhage due to the presence of anti-coagulation factors,which may be explained by the eosinophils,antibodies to the coagulation factors,and fibrinolytic system hyperactivity or inhibition.
Autoantibodies
;
Blister
;
Blood Coagulation Disorders
;
complications
;
Blood Coagulation Factors
;
Eosinophils
;
Hemorrhage
;
etiology
;
Humans
;
Mucous Membrane
;
pathology
;
Pemphigoid, Bullous
;
complications
;
Skin
;
pathology
;
Thrombosis
;
etiology
9.Basic research of fibrosis on atherosclerotic plaque stability and related drug application.
Jie YIN ; Qi LI ; Zheng ZHAO ; Qing YANG ; Yu-Jie LI ; Ying CHEN ; Ya-Jie WANG ; Xiao-Gang WENG ; Wei-Yan CAI ; Xiao-Xin ZHU
China Journal of Chinese Materia Medica 2019;44(2):235-241
In the background of the high incidence and high mortality of cardiovascular diseases,atherosclerosis is the main pathological feature of cardiovascular diseases and the core pathological basis for disease progression. In the evolution of atherosclerotic plaques,the rupture of unstable plaques,plaque shedding and formation of thrombosis are the most dangerous parts. In this process,the formation of plaque fibrosis is the core mechanism regulating plaque stability. Additionally,fibrosis reflects dynamic changes in the inflammatory processes and pathological changes. In view of the inflammation regulation and fibrosis regulation,this paper clarified the process of atherosclerotic plaque,explained the roles of relevant inflammatory cells and cytokines in plaque stability,and summed up drug researches related with stable plaque in recent years. In the future,improving the fibrosis will be a new idea for stabilizing plaque in atherosclerosis drug development.
Atherosclerosis
;
drug therapy
;
pathology
;
Cytokines
;
Fibrosis
;
Humans
;
Inflammation
;
Plaque, Atherosclerotic
;
drug therapy
;
pathology
;
Thrombosis
;
drug therapy
;
pathology
10.Research Progress?on?Age?Determination?of?Venous?Thrombosis in Forensic Medicine.
Lin Lin WANG ; Fu Yuan ZHANG ; Xue Ying LIANG ; Chang Liang WANG ; Rui ZHAO ; Da Wei GUAN
Journal of Forensic Medicine 2019;35(2):171-177
Pulmonary thromboembolism (PTE), which is caused by detachment of venous thrombosis, is a common cause of sudden death in forensic practice. In the cases which die of PTE after trauma or die of PTE during non-thrombosis disease hospitalization, forensic pathologists are required to analyze the time sequence between trauma or medical practice and venous thrombosis, and then analyze their causal relationship. This review summarizes the history of thrombus age estimation and recent advances in forensic medicine, and then gives a brief outlook for future research to provide reference for forensic identification of PTE and guide follow-up studies.
Age Determination by Skeleton
;
Death, Sudden
;
Forensic Medicine
;
Forensic Pathology/trends*
;
Humans
;
Pulmonary Embolism
;
Venous Thrombosis

Result Analysis
Print
Save
E-mail